Systemic administration of etretin increases epidermal interleukin I in the rat

We have studied the effect of systemic administration of etretin (Ro 10–1670) on the epidermal interleukin I (ILI) pool in the rat. Hairless rats were given varying doses of etretin intraperitoneally for 21 days, or a fixed dose for 2, 8 and 16 days. Abdominal skin was taken and processed for light microscopy, autoradiography (using [3H]‐thymidine) and ILI assays. ILI was assayed in supernatants of epidermal extracts by both the lymphocyte activating factor (LAP) assay and the stimulation of prostaglandin E2 (PGE2) release from dermal fibroblasts. A significant increase in both LAF and PGE2 stimulatory activities was found during etretin administration. After 21 days’ treatment with varying doses there was a two‐ to three‐fold increase as compared to the controls, with a peak at 2 and 5 mg/kg. At a fixed dose a two‐fold increase was found after 2 days and a three‐ to four‐fold increase after 16 days; normal pretreatment values were restored 16 days after cessation of etretin.

[1]  Y. Endo,et al.  Mechanism of in vitro antitumor effects of interleukin 1 (IL 1). , 1986, Immunobiology.

[2]  J. Saurat,et al.  Intracellular epidermal interleukin 1-like factors in the human epidermoid carcinoma cell line A431. , 1986, Cellular immunology.

[3]  J. Saurat,et al.  Interleukin 1 is present in normal human epidermis. , 1986, Journal of immunology.

[4]  I. Fidler,et al.  Natural and recombinant human interleukin 1-beta is cytotoxic for human melanoma cells. , 1986, Journal of immunology.

[5]  K. Resch,et al.  Macrophage cytotoxicity: interleukin 1 as a mediator of tumor cytostasis. , 1986, Journal of immunology.

[6]  H. Tagami,et al.  Interleukin-1-like activity in horny layer extracts: decreased activity in scale extracts of psoriasis and sterile pustular dermatoses. , 1986, Dermatologica.

[7]  B. Aggarwal,et al.  Human interleukin 1 is a cytocidal factor for several tumor cell lines. , 1985, Journal of immunology.

[8]  G. Seymour,et al.  The in vitro effect of retinol on human gingival epithelium. II. Modulation of Langerhans cell markers and interleukin-1 production. , 1985, The Journal of investigative dermatology.

[9]  G. Hunninghake,et al.  Epidermal cell-derived thymocyte activating factor (ETAF) is a potent T-cell chemoattractant. , 1985, The Journal of investigative dermatology.

[10]  R. Daynes,et al.  Presence of epidermal-derived thymocyte activating factor/interleukin 1 in normal human stratum corneum. , 1985, The Journal of clinical investigation.

[11]  H. Fleisch,et al.  Stimulation of interleukin 1 and 3 production by retinoic acid in vitro. , 1985, The Biochemical journal.

[12]  D. Sauder.  Biologic properties of epidermal cell thymocyte-activating factor (ETAF). , 1985, The Journal of investigative dermatology.

[13]  J. Saurat,et al.  Clinical Efficacy of Ro 10-1670, the Main Metabolite of Tigason , 1985 .

[14]  P. Elias,et al.  Retinoid Effects on Epidermal Differentiation , 1985 .

[15]  R. Edelson,et al.  Effects of Retinoids on the Immune System1 , 1985 .

[16]  S. Durum,et al.  Interleukin 1: an immunological perspective. , 1985, Annual review of immunology.

[17]  K. Frei,et al.  [Interleukin 1]. , 1985, Schweizerische medizinische Wochenschrift.

[18]  J. Dayer,et al.  Synthesis of interleukin 1/endogenous pyrogen in the brain of endotoxin-treated mice: a step in fever induction? , 1984, Journal of immunology.

[19]  R. Kampschmidt,et al.  The Numerous Postulated Biological Manifestations of Interleukin‐1 , 1984, Journal of leukocyte biology.

[20]  C. Carter,et al.  Epidermal cell production of thymocyte activating factor (ETAF). , 1982, The Journal of investigative dermatology.

[21]  S. Stošić-Grujičić,et al.  Modulation of interleukin 1 production by activated macrophages: in vitro action of hydrocortisone, colchicine, and cytochalasin B. , 1982, Cellular immunology.

[22]  B. Stadler,et al.  Epidermal cell (keratinocyte)-derived thymocyte-activating factor (ETAF). , 1981, Journal of immunology.

[23]  N. Sidell,et al.  Augmentation of human thymocyte proliferative responses by retinoic acid. , 1981, Experimental cell biology.

[24]  C. Orfanos,et al.  Chemotherapy of psoriasis and other skin disorders with oral retinoids. , 1981, Pharmacology & therapeutics.

[25]  C. Brinckerhoff,et al.  Inhibition by retinoic acid of collagenase production in rheumatoid synovial cells. , 1980, The New England journal of medicine.

[26]  S. Krane,et al.  Participation of monocyte-macrophages and lymphocytes in the production of a factor that stimulates collagenase and prostaglandin release by rheumatoid synovial cells. , 1979, The Journal of clinical investigation.

[27]  S. Mizel.  Physicochemical characterization of lymphocyte-activating factor (LAF). , 1979, Journal of immunology.

[28]  J. Voorhees,et al.  Glucocorticoid inhibits elevated polyamine biosynthesis in psoriasis. , 1978, The Journal of investigative dermatology.

[29]  C. D. Morley,et al.  A modified fluorometric method for the determination of microgram quantities of DNA from cell or tissue cultures. , 1976, Analytical biochemistry.

[30]  L. Levine,et al.  Specificities of Prostaglandins B1, F1α, and F2α Antigen-Antibody Reactions , 1971 .

[31]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.